• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Diseases & Conditions
  • All Diseases and Conditions

  • A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients with Recurrent or Refractory Acute Myelogenous Leukemia

Disease
acute myeloid leukaemia
Drug Name
AstraZeneca Oncology and Infection Development Drugs
Generic Name
AZD1208
Sponsor
AstraZeneca
Drug Status
In Development
Phase
I
Start Date
Jan 18, 1971
Study Name
D4510C00001
Study Id
D4510C00001
ClinicalTrials.gov ID

NCT01489722

Recruiting Status
Open
Protocol Status
Not Available
Report Status
Not Available

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013